1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
FSD Pharma Inc.

FSD Pharma Inc.

HUGE.CN
FSD Pharma Inc.CA flagCanadian Securities Exchange
0.13
CAD
-0.02
- -
88,576.00Market Cap
FSD Pharma Inc.
HUGE.CN
(Canadian Securities Exchange)

Recent

price

0.13

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
- -
- -
0.2
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.32
-0.29
-0.19
-27.75
-183.53
-360.45
-171.62
-65.63
-39.62
-29.39
-12.09
Basic EPS, GAAP
- -
-0.27
-0.21
-61.44
-182.02
-132.78
-103.25
-39.52
-48.16
-17.78
-8.32
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.99
-2.3
-2.58
69.3
336.29
135.13
66.59
48.68
-1.26
-33.05
-35.95
Book Value per Share
-0.58
-0.54
-0.75
97.74
412.42
179.23
123.5
70.55
31.05
12.4
8.18
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-13,585.61
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
2
4
4
5
3
1
Depreciation Expense
- -
- -
- -
-3
-17
-39
-32
-35
-24
-18
-7
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-13,585.61
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
3
15
2
21
37
10
7
5
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
10
37
36
36
54
31
13
10
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-88.81
-173.06
-235.48
-183.26
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
47
38
9

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
11
9
10
Cash, Cash Equivalents & STI
4
2
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
4
5
Payables & Accruals
4
3
4
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-11.06%
-57.73%
Free Cash Flow
- -
0.75%
-62.27%
Net Income, GAAP
- -
13.93%
-24.17%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-9.6
-7.47
-12.13
- -
-39.62
2023
-16.61
-9.1
-1.88
- -
-29.39
2024
-3.12
-4.85
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Peak Fpo [pkp] (PKP.AX)
Jilin Zixin Pharmaceutical Industrial Co.,Ltd. (002118.SZ)
Supernus Pharmaceuticals, Inc. (SUPN)
Kotra Industries Berhad (0002.KL)
Cipher Pharmaceuticals Inc. (CPH.TO)
Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ)
Business
Quantum BioPharma Ltd. (CSE: QNTM), formerly FSD Pharma Inc. (Ticker: HUGE.CN), develops innovative biopharmaceutical solutions targeting neurodegenerative disorders, neuropsychiatric conditions, inflammatory diseases, and alcohol misuse; its core pipeline includes Lucid-MS (Lucid-21-302), a patented new chemical entity that prevents and reverses myelin degradation in preclinical models for multiple sclerosis and other neurodegenerative diseases, with Phase 1 clinical trials for first-in-human safety and tolerability completed in healthy volunteers; unbuzzd, a science-backed functional beverage led by its subsidiary Celly Nutrition Corp. that supports mental alertness, detoxification, and recovery from acute alcohol intoxication through rapid metabolism assistance, backed by institutional review board approvals and partnerships such as with Six+One and option agreements with the University of Southern California for novel dietary supplement technologies; and exploratory formulations for weight loss and liver health. The company maintains a world-class research team including Julia Levy Award recipient Dr. Lakshmi Kotra from the Krembil Brain Institute and University Health Network, with operations focused on drug development in Canada and the US. Founded in 2016 and headquartered at 199 Bay Street, Suite 4000, Toronto, Ontario, M5L 1A9, Canada, with prior offices in Sparks, Maryland, Quantum BioPharma completed a 65:1 share consolidation and name change from FSD Pharma Inc. in August 2024, transitioning trading to the new ticker QNTM on Nasdaq and CSE while retaining a debt-free balance sheet with sufficient working capital for 2025 operations; recent initiatives encompass expanding its pipeline via Celly Nutrition investments, securing contracts for unbuzzd development, and advancing Lucid-MS toward potential first-in-class status in the $23 billion multiple sclerosis market and broader $238 billion mental health sector.